News

Loan amendment

March 30, 2022

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited ("VIM") (the “Loan”).  The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 30 June 2023 (previously 1 May 2022) (the “Loan Amendment”). 

Notice of Results

March 29, 2022

The Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2022, at the time of announcing the 2021 full year results which are scheduled for announcement on Thursday, 31 March 2022.

 

Year End Trading Update

February 03, 2022

Proteome Sciences today provides an unaudited trading update for the financial year ended 31 December 2021.

Substantial contract win for Proteome Sciences

December 20, 2021

Proteome Sciences is pleased to announce that the Company has secured a contract in excess of GBP 1 million from a major pharmaceutical company to analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022 and the majority of revenue is expected to be generated in 2022.

Proteome Sciences and INmune Bio to present biomarker discovery data at Clinical Trials in Alzheimer’s Disease 2021, Boston

November 05, 2021

Proteome Sciences and INmune Bio to present biomarker discovery data at Clinical Trials in Alzheimer’s Disease 2021, Boston

Interim results for the six months ended 30 June 2021

July 29, 2021

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2021.

Loan amendment to enable conversion into ordinary shares

June 18, 2021

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited ("VIM") (the “Loan”).  On 30 March 2021, the Company announced that the Loan had been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest (£59,657 as at 31 May 2021) is now repayable on 1 May 2022 (“Drawn Loan”).

The Directors of the Company are now pleased to announce that the Loan has been amended such that until 30 April 2022, VIM may convert part (being not less than £50,000 or a multiple thereof) or all of the Drawn Loan and accrued interest to 31 December 2020 (being £51,538) into new ordinary shares of the Company (the “Loan Amendment”). 

Grant of Options and PDMR/director shareholdings

June 08, 2021

Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company (“Ordinary Shares”) under the Company’s share option schemes (“Options”). A total of 14,000,000 Options have today been issued to three directors of the Company.

Issuance of key TMT Patent and Introduction of 18plex TMTpro Services

May 20, 2021

Proteome Sciences is pleased to announce the issuance to it of U.S. Patent No. 10,976,321 relating to methods of analysis using isobaric mass tags.

Change of registered office

May 18, 2021

The directors of Proteome Sciences announce that the Company’s registered office address has changed to 5 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey, KT15 2HJ with immediate effect.